Payment overview · 2025
General Payments
$1,463.93
74 reported records · 14 companies
Healthcare provider profile · identity verified
Janee' Routh Steele, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · TUPELO, MS · NPI 1669854964
Verified facts
What the public records show
CMS Open Payments records show Janee' Routh Steele, D.O. received $1,463.93 in general payments during 2025 across 74 reported records.
AstraZeneca Pharmaceuticals LP accounted for 33.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $491.04 | 33.5% | 22 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $245.30 | 16.8% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $184.66 | 12.6% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $86.48 | 5.9% | 5 | 2025 |
| QOL Medical, LLC | Unresolved — no canonical attribution shown | $82.28 | 5.6% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $74.91 | 5.1% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $70.18 | 4.8% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $53.82 | 3.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.47 | 3.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.08 | 3.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.47 | 1.9% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.69 | 1.4% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $16.80 | 1.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.75 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,463.93 | 74 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $281.45 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $228.75 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $186.14 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $171.02 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $169.74 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $149.20 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $133.18 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $128.73 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $86.48 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $86.13 | 4 | 2025 |
Source payment records
|
|||||
| Sucraid Normalized: sucraid |
Drug | QOL Medical, LLC | $82.28 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $50.44 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $49.47 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.47 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $46.08 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $16.80 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $8.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 83 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 133 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 78 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 115 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
83 | 18 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
133 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
133 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
78 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
115 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
113 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 908 | 213 |
| Amlodipine Besylate | Amlodipine Besylate | 626 | 163 |
| Losartan Potassium | Losartan Potassium | 517 | 132 |
| Famotidine | Famotidine | 317 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 307 | 64 |
| Gabapentin | Gabapentin | 306 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 285 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 279 | 70 |
| Metformin Hcl Er | Metformin Hcl | 234 | 74 |
| Spironolactone | Spironolactone | 216 | 58 |
| Omeprazole | Omeprazole | 215 | 40 |
| Carvedilol | Carvedilol | 197 | 50 |
| Meloxicam | Meloxicam | 189 | 44 |
| Potassium Chloride | Potassium Chloride | 187 | 52 |
| Mirtazapine | Mirtazapine | 173 | 28 |
| Levothyroxine Sodium | Levothyroxine Sodium | 171 | 43 |
| Ezetimibe | Ezetimibe | 156 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 144 | 38 |
| Lisinopril | Lisinopril | 140 | 34 |
| Metformin Hcl | Metformin Hcl | 137 | 37 |
| Jardiance | Empagliflozin | 133 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 69 |
| Duloxetine Hcl | Duloxetine Hcl | 127 | 30 |
| Ozempic | Semaglutide | 115 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 17 |
| Eliquis | Apixaban | 113 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 111 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 108 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 107 | 28 |
| Buspirone Hcl | Buspirone Hcl | 104 | 28 |
| Glimepiride | Glimepiride | 104 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 104 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 96 | 13 |
| Donepezil Hcl | Donepezil Hcl | 93 | suppressed |
| Furosemide | Furosemide | 92 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 92 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 87 | 20 |
| Allopurinol | Allopurinol | 83 | 24 |
| Farxiga | Dapagliflozin Propanediol | 83 | 18 |
| Clonidine Hcl | Clonidine Hcl | 80 | 25 |
| Mounjaro | Tirzepatide | 78 | 19 |
| Montelukast Sodium | Montelukast Sodium | 77 | 20 |
| Sucralfate | Sucralfate | 73 | 12 |
| Alprazolam | Alprazolam | 72 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 21 |
| Simvastatin | Simvastatin | 70 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 70 | 19 |
| Topiramate | Topiramate | 69 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 65 | 14 |
| Clonidine | Clonidine | 65 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | suppressed |
| Chlorthalidone | Chlorthalidone | 59 | 13 |
| Divalproex Sodium | Divalproex Sodium | 58 | suppressed |
| Memantine Hcl | Memantine Hcl | 58 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 20 |
| Januvia | Sitagliptin Phosphate | 54 | 11 |
| Trazodone Hcl | Trazodone Hcl | 53 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | suppressed |
| Lovastatin | Lovastatin | 52 | 14 |
| Warfarin Sodium | Warfarin Sodium | 52 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 51 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 49 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 42 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 11 |
| Torsemide | Torsemide | 37 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 21 |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Fluconazole | Fluconazole | 33 | 25 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Glipizide Er | Glipizide | 32 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 32 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Nystatin | Nystatin | 31 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 12 |
| Irbesartan | Irbesartan | 28 | suppressed |
| Kerendia | Finerenone | 27 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 17 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Triamterene | Triamterene | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,463.93 · 74 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, FARXIGA, JARDIANCE, JOURNAVX, Kerendia, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, OFEV, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, Sucraid, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error